Table I.
Baseline characteristics of study participants.
| Non‐users | Contraceptive users | Gestodene | Desogestrel | Levonorgestrel | Cyproterone | |
|---|---|---|---|---|---|---|
| Cases, n = 1426* | 349 | 1073 | 115 | 267 | 452 | 115 |
| Mean age in years (range) | 41 (19–50) | 36 (18–50) | 36 (20–49) | 35 (18–50) | 37 (18–50) | 32 (18–50) |
| Without family history, n (%) | 212/289 (73·4) | 703/920 (76·4) | 75/100 (75) | 174/226 (77·0) | 296/393 (75·3) | 80/98 (81·6) |
| With family history † , n (%) | 77/289 (26·6) | 217/920 (23·6) | 25/100 (25) | 52/226 (23·0) | 97/393 (24·7) | 18/98 (18·4) |
| Without F5 | 266/294 (90·5) | 800/976 (82·0) | 87/104 (83·7) | 209/248 (84·3) | 328/410 (80·0) | 83/104 (79·8) |
| With F5 | 28/294 (9·5) | 176/976 (18·0) | 17/104 (16·3) | 39/248 (15·7) | 82/410 (20·0) | 21/104 (20·2) |
| Without F2 | 275/294 (93·5) | 925/976 (94·8) | 99/104 (95·2) | 237/248 (95·6) | 384/410 (93·7) | 97/104 (93·3) |
| With F2 | 19/294 (6·5) | 51/976 (5·2) | 5/104 (4·8) | 11/248 (4·4) | 26/410 (6·3) | 7/104 (6·7) |
| Without F5 or F2 | 247/294 (84·0) | 759/976 (77·8) | 82/104 (78·8) | 200/248 (80·6) | 307/410 (74·9) | 79/104 (76·0) |
| With F5 or F2 | 47/294 (16·0) | 217/976 (22·2) | 22/104 (21·2) | 48/248 (19·4) | 103/410 (25·1) | 25/104 (24·0) |
| Without FGG | 130/295 (44·1) | 430/976 (44·1) | 45/104 (43·3 | 120/248 (48·4) | 177/410 (43·2) | 37/104 (35·6) |
| With FGG | 165/295 (55·9) | 546/976 (55·9) | 59/104 (56·7) | 128/248 (51·6) | 233/410 (56·8) | 67/104 (64·4) |
| Controls, n= 1777* | 1071 | 699 | 67 | 105 | 353 | 61 |
| Mean age in years (range) | 40 (18–50) | 34 (18–50) | 35 (19–49) | 34 (20–50) | 34 (18–50) | 31 (19–49) |
| Without family history, n (%) | 771/897 (86·0) | 519/578 (89·8) | 54/58 (93·1) | 78/87 (89·7) | 267/298 (89·6) | 43/49 (87·8) |
| With family history † , n (%) | 126/897 (14·0) | 59/578 (10·2) | 4/58 (6·9) | 9/87 (10·3) | 31/298 (10·4) | 6/49 (12·2) |
| Without F5 | 745/797 (93·5) | 463/487 (95·1) | 51/55 (92·7) | 70/75 (93·3) | 236/247 (95·5) | 38/38 (100) |
| With F5 | 52/797 (6·5) | 24/487 (4·9) | 4/55 (7·3) | 5/75 (6·7) | 11/247 (4·5) | 0/38 (0) |
| Without F2 | 785/797 (98·5) | 481/487 (98·8) | 53/55 (96·4) | 75/75 (100) | 244/247 (98·8) | 38/38 (100) |
| With F2 | 12/797 (1·5) | 6/487 (1·2) | 2/55 (3·6) | 0/75 (0) | 3/247 (1·2) | 0/38 (0) |
| Without F5 or F2 | 733/797 (92·0) | 457/487 (93·8) | 49/55 (89·1) | 70/75 (93·3) | 233/247 (94·3) | 38/38 (100) |
| With F5 or F2 | 64/797 (8·0) | 30/487 (6·2) | 6/55 (10·9) | 5/75 (6·7) | 14/247 (5·7) | 0/38 (0) |
| Without FGG | 432/802 (53·9) | 258/488 (52·9) | 25/55 (45·5) | 43/75 (57·3) | 129/248 (52·0) | 24/38 (63·2) |
| With FGG | 370/802 (46·1) | 230/488 (47·1) | 30/55 (54·5) | 32/75 (42·7) | 119/248 (48·0%) | 14/38 (36·8%) |
F5, Factor V Leiden rs6025; F2, (prothrombin) F2 rs1799963; FGG, fibrinogen gamma rs2066865.
*
Type of contraceptive used is missing for 16 cases and 19 controls. Of 4 cases and 7 controls it was not known whether they were users or non‐users.
†
With family history is defined as having at least one parent or sibling with a history venous thrombosis.